Citations

Clear

3942 citation(s) found for "To, Van".

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials
Zouboulis, Christos C. , Kyrgidis, Αthanassios , Alavi, Afsáneh , Wozniak, Magdalena B. , Martinez, Angela Llobet, Kasparek, Torben, Bachhuber, Teresa, Ortmann, Christine-Elke, Lobach, Iryna , Thomas, Nicolas, Ravichandran, Shoba, Kyrgidis, Athanassios , Marzano, Angelo Valerio , Alavi, A , Zouboulis, Christos C , Jemec, Gregor B. E. , Martorell, Antonio , Zee, Hessel H. van der , Lobach, Iryna, Thomas, Nicolas, Tzellos, Thrasyvoulos

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | October 19, 2024 | Volume: 39 | Issue: 8 | Pages: 1421-1430

10.1111/jdv.20369 | PMID 39425517 Get It

AbstractIntroductionThe International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS).ObjectiveTo evaluate secukinumab efficacy using IHS4 in patients with moderate to severe HS.MethodsData from the SUNSHINE and SUNRISE trials, which assessed subcutaneous secukinumab 300 mg every 2 (SECQ2W) and 4 (SECQ4W) weeks in adults with moderate to severe HS, were analyzed. Assessments included changes from baseline in IHS4 and severity classification up to Week 52; IHS4‐55, IHS4‐75, IHS4‐90 responses (55%, 75% and 90% reduction in IHS4) and concordance between IHS4‐55 and HS clinical response (HiSCR), at Weeks 16 and 52.ResultsIn total, 1084 patients (SECQ2W = 361; SECQ4W = 360; placebo = 363) were analyzed. At Week 16, SECQ2W and SECQ4W demonstrated a numerically higher reduction in IHS4 from baseline versus placebo (adjusted mean [95% CI]: −10.80 [−12.30 to −9.30] and −9.46 [−10.96 to −7.96] vs. −4.92 [−6.43 to −3.41]); the reduction was maintained until Week 52 in both dose regimens. A greater proportion of patients achieved IHS4‐55 with SECQ2W (43.4%) and SECQ4W (39.5%) versus placebo (31.5%) at Week 16, with further improvement at Week 52. Similar trends were observed for IHS4‐75 and IHS4‐90 responses. While no patients had mild disease based on IHS4 (80.7% had severe and 19.3% had moderate HS) at baseline, a greater proportion of patients were categorized as having mild disease at Week 16 in the SECQ2W (25.9%) and SECQ4W (24.0%) groups versus placebo (16.4%); this trend continued up to Week 52 in both dose regimens. Strong concordance (>85%) was observed between IHS4‐55 and HiSCR.ConclusionsBoth SECQ2W and SECQ4W demonstrated efficacy in improving treatment response as measured by IHS4 and reducing disease severity versus placebo at Week 16 and these improvements were sustained through Week 52. These findings support that the dynamic and dichotomous IHS4 can efficiently detect treatment response changes in clinical trial settings.Clinical Trials RegistrationSUNSHINE (NCT03713619); SUNRISE (NCT03713632).
Rates and predictors of loss to follow-up for sporadic vestibular schwannomas undergoing imaging surveillance
Alexander, Marcus, Sáez-Alegre, Miguel , Celda, María Peris, Neff, Brian A., Carlson, Matthew L. , Driscoll, Colin L. W., Link, Michael J. , Peris Celda, Maria, Driscoll, Colin L., Morshed, Ramin A. , Bauman, Megan M. J. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | October 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.3171/2024.6.jns232904 | PMID 39423436 Get It

OBJECTIVE Imaging surveillance with serial MRI, or a "wait-and-scan" approach, is a management option for patients with small or medium-sized vestibular schwannomas (VSs). Prior publications have indicated no distinct quality of life advantage to upfront treatment compared with initial wait-and-scan management. However, imaging surveillance is dependent on patient adherence to follow-up. In this study, the authors aimed to identify rates and predictors of patient loss to follow-up during wait-and-scan management of sporadic VS. METHODS A single-center study was conducted including all patients from 2013 to 2018 who had undergone upfront imaging surveillance of sporadic VS. Patient data were retrospectively obtained from the electronic medical record. Outcomes of interest included loss to follow-up unrelated to death and inconsistent adherence to imaging surveillance recommendations. Logistic regression analyses were conducted to evaluate factors associated with loss to follow-up. RESULTS Over a 6-year study period, 270 patients underwent initial imaging surveillance of a sporadic VS. The median tumor diameter was 8.6 mm (range 1–28.9 mm). At the time of censoring, 106 patients (39.3%) had received treatment, 157 (58.1%) had been advised to continue follow-up, and 7 (2.6%) had died of non–VS-related causes. In total, 73 patients (27.0%) were completely lost to follow-up prior to the first treatment or death. Additionally, 60 patients (22.2%) missed at least 1 MRI follow-up or imaging follow-up was delayed by more than 1 year. Multivariable logistic regression identified an out-of-state residence (OR 3.05, 95% CI 1.58–5.89, p = 0.0009) and a smaller tumor size (unit OR per 1-mm increase in size, OR 0.88, 95% CI 0.83–0.95, p = 0.0006) to be associated with loss to follow-up. Patients living ≥ 350 miles from the hospital or with tumors ≤ 3 mm at the time of initial clinic evaluation were most likely to be lost to follow-up. Only a smaller tumor size was associated with an increased risk of inconsistent imaging follow-up (unit OR per 1-mm increase in size, OR 0.92, 95% CI 0.87–0.98, p = 0.007). CONCLUSIONS Patients undergoing imaging surveillance of VS are at risk for loss to follow-up and inconsistent imaging surveillance. Patients with smaller tumors or those living farther away from the treating institution are at highest risk for being lost to follow-up.
Three-Year Outcomes Following TAVR in Younger (
Modine, Thomas , Tchétché, Didier , Mieghem, Nicolas M. Van , Deeb, G. Michael , Chetcuti, Stanley, Yakubov, Steven J. , Sorajja, Paul , Gada, Hemal, Mumtaz, Mubashir , Ramlawi, Basel , Bajwa, Tanvir , Crouch, John , Teirstein, Paul S., Kleiman, Neal S. , Iskander, Ayman, Chu, Michael , Sudre, Arnaud , Huang, Jian, Popma, Jeffrey J. , Forrest, John K. , Van Mieghem, Nicolas M , Bagur, Rodrigo , Chu, Michael W A , Berthoumieu, Pierre , Sudre, Arnaud , Adrichem, Rik , Ito, Saki , Forrest, John K , Modine, Thomas , Sorajja, Paul , Bagur, Rodrigo , Ito, Saki , Huang, Jian Qun , Reardon, Michael J.

Mayo Clinic

Circulation: Cardiovascular Interventions | October 18, 2024 | Volume: 17 | Issue: 11 | Pages: No page available

10.1161/circinterventions.124.014018 | PMID 39421943 Get It

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis, but data are limited on younger, low-risk patients. This analysis compares outcomes in low-surgical-risk patients aged <75 years receiving TAVR versus surgery. METHODS: The Evolut Low Risk Trial randomized 1414 low-risk patients to treatment with a supra-annular, self-expanding TAVR or surgery. We compared rates of all-cause mortality or disabling stroke, associated clinical outcomes, and bioprosthetic valve performance at 3 years between TAVR and surgery patients aged <75 years. RESULTS: In patients <75 years, 352 were randomized to TAVR and 351 to surgery. Mean age was 69.1±4.0 years (minimum 51 and maximum 74); Society of Thoracic Surgeons Predicted Risk of Mortality was 1.7±0.6%. At 3 years, all-cause mortality or disabling stroke for TAVR was 5.7% and 8.0% for surgery ( P =0.241). Although there was no difference between TAVR and surgery in all-cause mortality, the incidence of disabling stroke was lower with TAVR (0.6%) than surgery (2.9%; P =0.019), while surgery was associated with a lower incidence of pacemaker implantation (7.1%) compared with TAVR (21.0%; P <0.001). Valve reintervention rates (TAVR 1.5%, surgery 1.5%, P =0.962) were low in both groups. Valve performance was significantly better with TAVR than surgery with lower mean aortic gradients ( P <0.001) and lower rates of severe prosthesis-patient mismatch ( P <0.001). Rates of valve thrombosis and endocarditis were similar between groups. There were no significant differences in rates of residual ≥moderate paravalvular regurgitation. CONCLUSIONS: Low-risk patients <75 years treated with supra-annular, self-expanding TAVR had comparable 3-year all-cause mortality and lower disabling stroke compared with patients treated with surgery. There was significantly better valve performance in patients treated with TAVR. REGISTRATION: URL: https://clinicaltrials.gov ; Unique identifier: NCT02701283.
Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASH
Coombes, Jason D. , Manka, Paul , Swiderska‐Syn, Marzena , Vannan, Danielle T. , Riva, Antonio , Claridge, Lee C., Moylan, Cynthia A. , Suzuki, Ayako , Younis, Rasha, Sydor, Svenja , Bittencourt, Shanna, Mi, Zhiyong, Kuo, Paul C. , Diehl, Anna Mae , Grunsven, Leo A. van , Chokshi, Shilpa , Papa, Salvatore , Eksteen, Bertus , Syn, Wing‐Kin, Sydor, Svenja , van Grunsven, Leo A , Canbay, Ali , Abdelmalek, Manal F. , Papa, Salvatore , Moylan, Cynthia A , Suzuki, Ayako , Briones-Orta, Marco Antonio , Kitamura, Naoto, Canbay, Ali , Aspichueta, Patricia

Mayo Clinic

Liver International | October 18, 2024 | Volume: 45 | Issue: 4 | Pages: No page available

10.1111/liv.16131 | PMID 39422353 Get It

ABSTRACT Background and Aims Osteopontin (OPN) promotes the ductular reaction and is a major driver of chronic liver disease (CLD) progression. Although CLD is characterised by the accumulation of inflammatory cells including macrophages around the peri‐portal regions, the influence of OPN on recruitment is unclear. We investigated the role of OPN in cholangiocyte chemokine production and macrophage recruitment by combining in vivo, in vitro, and in silico approaches. Methods The effects of OPN on cholangiocyte chemokine production and macrophage migration were assessed in culture, alongside RNA‐sequencing to identify genes and pathways affected by OPN depletion. Murine liver injury models were used to assess liver chemokine expression and liver macrophage/monocyte recruitment. OPN and chemokine expression were analysed in liver tissue and plasma from biopsy‐proven metabolic dysfunction‐associated alcoholic steatohepatitis (MASH) patients. Results OPN‐knockdown in cholangiocytes reduced chemokine secretion. RNA‐sequencing showed OPN‐related effects clustered around immunity, chemotaxis and chemokine production. Macrophage exposure to cholangiocyte‐conditioned media showed OPN‐supported migration via chemokines chemokine (C‐C motif) ligand (CCL)2, CCL5 and chemokine (C‐X‐C motif) ligand (CXCL)1. These effects were related to NF‐κB signalling. Murine liver fibrosis was accompanied by upregulated liver OPN, CCL2, CCL5 and CXCL1 mRNA, and accumulation of liver cluster of differentiation (CD)11b/F4/80 + CC chemokine receptors (CCR2) high macrophages but treatment with OPN‐specific neutralising aptamers reduced fibrosis, chemokine mRNAs and accumulation of liver CD11b/F4/80 + CCR2 high /lymphocyte antigen 6 complex high inflammatory monocytes. In human MASH, liver OPN correlated with chemokines CCL2 and IL8 in association with portal injury and fibrosis. Plasma OPN, serum CCL2 and IL8 also increased with fibrosis stage. Conclusions OPN promotes cholangiocyte chemokine secretion and the accumulation of pro‐inflammatory monocytes. These data support neutralisation of OPN as an anti‐inflammatory and anti‐fibrotic strategy.
The canine homolog of human receptive speech area responds selectively to social reinforcement
Miller, Kai J. , Lampert, F. , Kim, Inyong , Ince, Nuri F. , Hermes, Dora, Lampert, Frederik, Mívalt, Filip , Kim, Jiwon W. , Křemen, Václav , Baker, Matthew , Boom, Max van den , Hermes, Dora , Coenen, Volker Arnd , Schalk, Gerwin , Brunner, Peter , Worrell, Gregory A.

Mayo Clinic

No container title available | October 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5183241/v1 Get It

Abstract Studying mammalian brain function aids our understanding of human brain evolution. We implanted a beagle with a prototype human neuromodulation platform that measures activity from the brain surface. One year later, a set of simple sensory tasks was performed, finding visual and somatosensory representation in the canine homologs of the expected areas in humans. Surprisingly, the canine anterior ectosylvian gyrus, which is anatomically homologous to human receptive speech areas, was selectively active during independent social reinforcement tasks. This suggests that human speech understanding may have evolved from more general mammalian brain structures that are specialized for social reinforcement.
An Integrated Approach to Improving Itinerary Completion in Coordinated Care Networks
Liu, Yiqiu , Oyen, Mark P. Van , Hucshka, Todd, Shi, Pengyi , Helm, Jonathan Eugene , Ying, Lei

Mayo Clinic

Manufacturing & Service Operations Management | October 15, 2024 | Volume: 27 | Issue: 1 | Pages: 21-39

10.1287/msom.2022.0649 Get It

Problem definition: Coordinated care network (CCN) is a burgeoning paradigm where patients’ diagnosis and treatment plans are developed based on collaboration between multiple, colocated medical specialties to holistically address patients’ health needs. A primary performance metric for CCNs is how quickly patients can complete their itinerary of appointments at multiple medical services in the network. Rapid completion is critical to care delivery but also presents a major operational challenge. Because information about a patient’s condition and treatment options evolves over the course of the itinerary, care paths are not known a priori. Thus, appointments (except for the first one) cannot be reserved in advance, which may result in significant delays if capacity is not allocated properly. Methodology/results: We study capacity allocation for the patient’s first (root) appointment as the primary operational lever to achieve rapid itinerary completion in CCNs. We develop a novel queueing-based analytical framework to optimize this root appointment allocation, maximizing the proportion of patients completing care by prespecified deadlines. Our framework accounts for the complex interactions among all patients in the network through the blocking process, which contrasts with conventional siloed planning. We provide an exact characterization of the itinerary time and develop a mean-field approximation with convergence guarantees that permits tractable solutions for large-scale network problems. In a simulation case study of Mayo Clinic, our solution improves on-time completion from 60% under the current plan to more than 93%. Managerial implications: We demonstrate that root appointment allocation is a multifaceted problem and that ignoring any of those facets can lead to poor performance. Simultaneously accounting for all of these complexities makes manual template design or traditional optimization methods inadequate, highlighting the significance of our integrated approach. Supplemental Material: The online appendix is available at https://doi.org/10.1287/msom.2022.0649 .
Exploration of the relationship between general health-related problems and subclinical coronary artery disease: a cross-sectional study in a general population
Koopman, Moniek Y. , Ende, M. Yldau van der , Reijnders, Jorn J W , Willemsen, Robert , Bruggen, Rykel van , Gratama, Jan W. , Kietselaer, Bas , Harst, Pim van der , Vliegenthart, Rozemarijn , Kietselaer, Bastiaan L J H, van der Harst, Pim , Kietselaer, Bas L J H , Koopman, Moniek , Vliegenthart, Rozemarijn

Mayo Clinic

BMJ Open | October 14, 2024 | Volume: 14 | Issue: 10 | Pages: e079835

10.1136/bmjopen-2023-079835 | PMID 39401960 Get It

Objective To explore associations between general health-related problems and subclinical coronary artery disease (CAD), determined by CT coronary calcium score (CT-CCS), in a general population. Design A cross-sectional design. Setting This study was performed in a prospective population-based cohort, examining the health and health-related behaviour of individuals living in the Northern Netherlands. Participants The initial cohort comprised 6763 participants ≥45 years of age who underwent CT-scanning. Participants were included for the current analysis if they filled in three validated questionnaires (Symptomatic Checklist-90, Research and Development Survey-36 and Reviving the Early Diagnosis of CardioVascular Diseases questionnaire (RED-CVD)) and did not have a history of cardiovascular disease. The final analysis included 6530 participants. Primary outcome measure Backward-stepwise and forward-stepwise logistic regression analyses were performed to determine associations between general health-related problems and subclinical CAD (CCS≥100 and ≥300). Results The median age was 53 years (25th, 75th percentile: 48, 58); 57% were women. CRCS≥100 was found in 1236 (19%) participants, 437 (12%) in women and 799 (29%) men and CCS≥300 in 643 (9.9%) participants of which 180 (4.8%) were women and 463 (16.6%) men. In univariate analysis, in women the expectation of health to worsen (OR=1.13, 95% CI: 1.05 to 1.21), and in men reduced exercise intolerance (OR=1.14, 95% CI: 1.06 to 1.23) were associated with CCS≥100. The total RED-CVD score in women (OR=1.06, (95% CI: 1.05 to 1.08) and men (OR=1.07, 95% CI: 1.06 to 1.09), and in men also reduced exercise intolerance (OR=1.15, 95% CI: 1.06 to 1.25) and headache (OR=0.55, 95% CI: 0.38 to 0.79) were associated with CCS≥300. In multivariate analyses, only general health expectation in women was still significantly associated with subclinical CAD (CCS≥300) (OR=1.92, 95% CI: 1.56 to 2.37). Conclusion Only a few general health-related problems were associated with the presence of subclinical CAD in the general population, however, these problems showed no strong association. Therefore, using health-related symptoms does not seem useful to pre-select for CT-CCS. Trial registration number CCMO Register, NL17981.042.07 and NL58592.042.16.
Clinical Utility of Neurophysiologic Classification (and Declassification) of Myoclonus
Callister, Marcus N. , Klanderman, Molly , Stockard, Alyssa , Walt, Charles Van Der , Peña, Ashley B. , Caviness, John N., Klanderman, Molly C, Van der Walt, Charles, Stockard, Alyssa , Walt, Charles Van Der

Mayo Clinic

Movement Disorders | October 14, 2024 | Volume: 39 | Issue: 12 | Pages: 2242-2248

10.1002/mds.30022 | PMID 39400359 Get It

Abstract Background Movement clinical neurophysiology studies can distinguish myoclonus, tremor, and other jerky movements; however, there has been limited demonstration of their real‐world clinical impact. Objective The aim was to investigate movement study utility in clarifying movement classification and guiding patient management. Method A retrospective study of myoclonus‐related movement studies was performed. Results Of 262 patients referred for consideration of myoclonus, 105 (40%) had myoclonus, 156 (59%) had no myoclonus (the commonest alternative classifications were functional jerks and tremor), and 1 was uncertain. An additional 29 studies identified myoclonus without prior clinical suspicion. A total of 119 of 134 (89%) myoclonus patients had a specific neurophysiologic subtype identified, most commonly cortical (64, 54%). Diagnostic differential narrowed in 60% of patients, and a new diagnosis was made in 42 (14%) patients. Medication changes were made in 151 patients (52%), with improvement in 35 of 51 (67%) with follow‐up. Conclusions Movement studies effectively determined movement classification and identified unsuspected myoclonus, leading to changes in diagnosis and management. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Alzheimer's disease clinical variants show distinct neuroinflammatory profiles with neuropathology
Boon, Baayla D.C. , Frigerio, Irene , Gooijer, Danae de, Morrema, Tjado H. J., Bol, John G. J. M., Graaf, Yvon Galis ‐ de, Bank, Netherlands Brain, Amsterdam, Normal Aging Brain Collection, Heymans, Martijn W. , Bank, Netherlands Brain, Murray, Melissa E. , Amsterdam, Normal Aging Brain Collection, Lee, Sven J. van der , Holstege, Henne H. , Berg, Wilma D. J. van de , Jonkman, Laura E. , Rozemüller, Annemieke J.M. , Bouwman, Femke H. , Hoozemans, Jeroen J.M.

Mayo Clinic

Neuropathology and Applied Neurobiology | October 14, 2024 | Volume: 50 | Issue: 5 | Pages: No page available

10.1111/nan.13009 | PMID 39400356 Get It

Abstract Aims Although the neuroanatomical distribution of tau and amyloid‐β is well studied in Alzheimer's disease (AD) (non)‐amnestic clinical variants, that of neuroinflammation remains unexplored. We investigate the neuroanatomical distribution of activated myeloid cells, astrocytes, and complement alongside amyloid‐β and phosphorylated tau in a clinically well‐defined prospectively collected AD cohort. Methods Clinical variants were diagnosed antemortem, and brain tissue was collected post‐mortem. Typical AD ( n = 10), behavioural/dysexecutive AD ( n = 6), posterior cortical atrophy (PCA) AD ( n = 3), and controls ( n = 10) were neuropathologically assessed for AD neuropathology, concurrent pathology including Lewy body disease, limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic change (LATE‐NC), and vascular pathology. For quantitative assessment, we analysed the corticolimbic distribution of phosphorylated tau, amyloid‐β, CD68, MHC‐II, C4b, and glial fibrillary acidic protein (GFAP) using digital pathology. Results Phosphorylated tau was distinctly distributed in each variant. In all variants, amyloid‐β was neocortical‐dominant, with a notable increase in the middle frontal cortex of behavioural/dysexecutive AD. Typical AD and PCA AD had no concurrent Lewy body disease, whereas three out of six cases with behavioural/dysexecutive AD did. LATE‐NC stage >0 was observed in three AD cases, two typical AD (stage 1/3), and one behavioural/dysexecutive AD (stage 2/3). Vascular pathology was present in each variant. In typical AD, CD68 and MHC‐II were hippocampal‐dominant. In behavioural/dysexecutive AD, C4b was elevated in the middle frontal and inferior parietal cortex. In PCA AD, MHC‐II was increased in the fusiform gyrus, and GFAP in parietal cortices. Correlations between AD neuropathology and neuroinflammation were distinct within variants. Conclusions Our data suggests that different involvement of neuroinflammation may add to clinical heterogeneity in AD, which has implications for neuroinflammation‐based biomarkers and future therapeutics.
Rapid and Accurate Diagnosis and Prognosis of Acute Infections and Sepsis from Whole Blood Using Host Response mRNA amplification and Result Interpretation by Machine-Learning Classifiers
Liesenfeld, Oliver , Arora, Sanjay , Aufderheide, T. P., Fischer, Miriam, Giamarellos‐Bourboulis, Evangelos J. , House, Stacey L. , Humphries, Roger L., Liu, Edward , Mace, Sharon E. , May, Larissa, Michelson, Edward A. , Panacek, Edward A., Self, Wesley H. , Smithline, Howard , Steingrub, Jay S. , Heukelom, Paul Van , Weissman, Alexandra , Wolk, Donna M. , Buturović, Ljubomir , Damaraju, Nandita , Lu, Cici, Whitfield, Natalie N. , Shapiro, Nathan I. , Giamarellos-Bourboulis, Evangelos J , Aufderheide, Tom P. , Clements, Casey M. , DeVos, Elizabeth , Fischer, Miriam, Gill, Jasreen Kaur , Osborn, Tiffany Medlin , Rothman, Richard Eric , Wilson, Matthew, Wright, David W. , Hasin-Brumshtein, Yehudit , Shak, Joshua R., Khatri, Purvesh , Sweeney, Timothy E.

Mayo Clinic

No container title available | October 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5194992/v1 Get It

Abstract Many patients in the emergency department present with signs and symptoms that arouse concern for sepsis; however, other explanations are also possible. There are currently no rapid tests used in clinical practice that reliably distinguish the presence of a bacterial or viral infection vs. a non-infectious etiology and can predict a patient’s likelihood to decompensate. The diagnostic and prognostic uncertainty in “gray zone” patients complicates the decision to begin therapy as clinicians need to balance the risk of withholding therapy vs. the risk of the therapy itself (e.g., overtreatment with antibiotics and hospitalization, which is costly, potentially harmful, and contributes to antibiotic resistance). The TriVerity™ Test uses isothermal amplification and machine-learning algorithms to quantify and interpret mRNA expression levels to determine both likelihood of bacterial infection, viral infection, or no infection, and whether the patient will likely require one or more critical interventions within 7 days. The three scores each fall into one of five interpretation bands ranging from Very high to Very low. Testing takes approximately 30 minutes using the proprietary Myrna™ Instrument with an operator hands-on-time of under one minute. We enrolled 1,222 patients from 22 emergency departments (ED) to validate the performance of the TriVerity Test. Patients were treated as per local standard of care and were followed for 28 days. Bacterial and viral TriVerity results were validated against clinically adjudicated infection status; the illness severity TriVerity result was validated against the need for at least one critical interventions within 7 days. The bacterial TriVerity result had high AUROC for the diagnosis of bacterial infection (0.83; 80% CI 0.81–0.85) and divided bacterial infection likelihood scores into five interpretation bands with increasing likelihood ratios of infection ranging from Very low (LR- 0.08, 80% CI 0.06–0.11) to Very high (LR + 8.04, 80% CI 5.72–11.78). The AUROC for the bacterial TriVerity result was significantly higher compared to AUROCs for C-reactive protein, procalcitonin or white blood cell count. Similarly, the viral TriVerity score showed high AUROC for the diagnosis of viral infection (0.91; 80% CI 0.90–0.93) and likelihood ratios from Very low (LR- 0.09, 80% CI 0.05–0.14) to Very high (LR + 40.93; 80% CI 29.11–79.23). The TriVerity Illness Severity score showed a high AUROC for the prediction of illness severity (0.77; 80% CI 0.77–0.81) with scores divided into five interpretation bands with increasing likelihood ratios ranging from Very low (LR- 0.22; 80% CI 0.14–0.33) to Very high (LR + 11.33; 80% CI 7.31–17.00). TriVerity illness severity results allowed marked re-classification of the risk for “ICU-level care” as compared to clinical assessment (qSOFA scores) alone. In conclusion, TriVerity provides rapid, highly accurate and actionable results for the diagnosis and prognosis of patients with suspected acute infection and/or sepsis, supporting a major unmet medical need. TriVerity may improve personalized management of patients with suspected acute infections and suspected sepsis for improved overall healthcare outcomes.